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Colorectal cancer screening: Why
immunochemical fecal occult blood tests may be
the best option
Kathy L Flitcroft*, Les M Irwig, Stacy M Carter, Glenn P Salkeld and James A Gillespie
Abstract
Background: There are many test options available for colorectal cancer screening. The choice of test relates to the
objectives of those offering or considering screening.
Discussion: While all screening programs aim to detect disease early in order to improve the length and/or quality
of life for the individual, some organizations and individuals prefer screening tests that offer the opportunity for
cancer prevention. Others favor maximizing participation or the opportunity for shared decision-making, including
discussion of information on test quality and availability. We propose three additional objectives for screening:
minimizing harms, optimizing economic efficiency and maximizing equity of access to screening.
Summary: Applying these objectives to colorectal cancer screening, we advocate the use of immunochemical
FOBTs as the preferred screening strategy, as it satisfies all three of these important objectives.
Keywords: Screening objectives, Colorectal cancer, Fecal occult blood testing, Harm minimization, Equity, Economic
efficiency, Prevention, Participation
Background
There is a wide range of tests that may be offered to
people considering colorectal cancer (CRC) screening.
These include tests which allow for visual inspection of
the bowel, such as colonoscopy and flexible sigmoidos-
copy; imaging tests such as computed tomographic (CT)
colonography, magnetic resonance (MR) colonography,
capsule endoscopy and double contrast barium enema; and
tests on fecal specimens such as fecal occult blood tests
(FOBTs) and stool DNA tests. The choice of test depends
to some extent on the preferences of the individuals
or groups making these decisions: different screening
objectives will favor different tests.
There are advantages and disadvantages to each test.
For example, tests that use visual or imaging-based in-
spection of the colorectum involve bowel preparation
that is unpleasant and potentially harmful. However,
these tests do not have to be performed as often as tests
that involve fecal sampling. Is it better to have a more
burdensome test less often than a simple test more
often? The answer depends in part on the implementa-
tion objectives of those offering the screening test and in
part on the view of the individual considering the
screening test.
All screening programs aim to detect disease early in
order to improve the average length and/or quality of life
for a population at risk of developing a particular
disease. Any cancer screening program must satisfy this
essential aim of reducing mortality and/or morbidity
from the disease being screened for, and this article does
not seek to downplay this fundamental criteria.
But all screening tests have the potential to cause
harm. Within each screening program, there is also a
range of other possible objectives – which can be
thought of as additional objectives – that aim to increase
the benefits of screening, or their distribution, in relation
to the harms. Like the essential criterion of mortality/
morbidity reduction, these additional objectives have moral
value, and different people will prioritize them differently
for different reasons.
For example, the US Multi-Society Task Force on
Colorectal Cancer has placed a priority on cancer
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prevention. This has led to a preference for screening tests
that are capable of detecting adenomatous polyps rather
than just cancer, “as long as resources are available and
patients are willing to undergo an invasive test” [1].
Preferred tests to satisfy this objective are flexible sigmoid-
oscopy every 5 years, colonoscopy every 10 years, double
contrast barium enema every 5 years or CT colonography
every 5 years.
In contrast, the focus of the US Preventive Services
Task Force is on strategies that maximize the number of
individuals who get screened, while emphasizing the
need for shared decision-making [2]. Recommended
options, based on these objectives, are annual screening
with high-sensitivity fecal occult blood test, sigmoidos-
copy every 5 years combined with high-sensitivity FOBT
every 3 years, and screening colonoscopy every 10
years. While recommending that participants be given
a choice among screening modalities, they do state that
“colonoscopy and flexible sigmoidoscopy (to a lesser
degree) entail possible serious complications” [2].
We recognize the validity of two of these objectives–
preventing cancer and encouraging shared decision-
making are both worthy aims, although they are potentially
contradictory (if individuals do not wish to undergo
invasive tests for initial screening). In contrast, we believe
that maximizing participation should not be a primary
aim of a screening program: not everyone will want to be
screened, and high screening participation rates are not
necessary to ensure cost-effectiveness [3]. The decision to
be screened is dependent on an individual’s assessment of
the relative benefits and downsides or harms for them
personally.
This potential contradiction between encouraging
shared decision-making and maximizing participation
is well recognized [1,4-6]. This tension arises from
differences in what is valued. If our objective is
shared decision-making, we are valuing respect for
individuals, expressed via an opportunity for people
to meaningfully consider whether they want to be
screened, and to receive services accordingly. Con-
versely, taking maximization of participation as a goal
places value on improving efficiency or meeting
targets. If maximizing participation is the goal, indivi-
duals should be actively encouraged to be screened,
regardless of the personal consequences. But, unlike
screening for infectious diseases, the benefits of cancer
screening are no greater than the sum of benefits to
each individual.
This article will not revisit these debates, but instead
will focus on three additional objectives that we argue
are equally worthy of consideration, not only for colo-
rectal cancer screening programs, but potentially for
any screening program, where a range of screening
modalities exist.
Discussion
This discussion first provides an overview of three
additional objectives for screening, followed by an
outline of how each of these objectives can be applied
to CRC screening.
Additional objectives
1) Minimization of harms.
In their seminal work on screening principles, Wilson
and Jungner [7] were among the first to warn that popu-
lation screening can cause harm to individuals. “In en-
thusiastically attacking disease at an early stage the
Hippocratic principle . . . of primum non nocere [first do
no harm] should not be neglected” [7]. Invariably, there
is a trade-off between the benefits of early detection for
a few individuals and the potential harms experienced
by a much larger number of individuals within an asymp-
tomatic screened population. This raises ethical concerns
regarding whether the benefits outweigh the harms and
how this can be determined. In fact, extensive screening
procedures are still being advocated without evidence of
their effectiveness, and despite their potential or actual
capacity to cause harm (see for example Law [8] on pros-
tate cancer screening and Wald [9] on CT body scanning).
Harm minimization, defined as minimizing the risk of
adverse consequences, is one important potential objective
of screening.
2) Optimization of economic efficiency.
Given the competition for scarce health funding, and
the potential opportunity costs involved in opting for
population screening over primary prevention or disease
treatment, it is crucial that screening is performed as
efficiently as possible to maximize the return on invest-
ment. The purpose of screening average risk persons is
not to diagnose a particular disease, but to identify those
at higher risk of having this disease. The screening
process is designed to limit the number of people who
are invited for more expensive follow-up of the initial
disease indicator. By separating the screening and diagnos-
tic tests, the funding and resources required for follow-up
are provided only to those most at risk of the disease, thus
producing cost savings and optimizing economic efficiency,
a second worthy objective of screening.
While all methods of CRC screening have been shown
to be cost-effective, FOBT screening has consistently
been reported to be highly cost-effective [10-13], so
much so that government funders in several countries
have established organized FOBT screening programs.
Population screening with more expensive tests, even if
they are performed less often, have not yet been publicly
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funded. However, following an RCT of flexible sigmoidos-
copy in the UK, [14] which did not include a cost-
effectiveness assessment, there are plans to add a one-off
flexible sigmoidoscopy test to the existing FOBT National
Health Service Bowel Cancer Screening Program for
people in England aged 55 [15]. Those aged over 60 will
continue to be offered biennial guaiac-based FOBT tests
(gFOBTs) that are known to be less accurate, but are less
expensive, than immunochemical FOBTs (iFOBTs).
The use of quantitative iFOBTs also has another
important advantage. It allows for greater flexibility as
screening program organizers can choose the cut-off
point for a positive result, ensuring resource considerations
and population preferences can be taken into account. This
is particularly important when colonoscopy capacity
is limited.
3) Maximization of equity of access.
Savings from redirection of resources away from
diagnostic tests and towards screening tests whose
focus is on identifying those in the population at
higher risk of disease could be used to address in-
equities in access to screening, by allowing all those
who stand to benefit from screening to access it if
they choose to do so. More funding would become
available to offer free screening to all those within
the target population the evidence has identified as
potentially benefiting more than harming.
Applying these additional objectives to colorectal cancer
screening
1) Minimization of harms.
There is high-level evidence about the benefits of
screening for CRC using fecal occult blood tests. Meta-
analysis of randomized controlled trial evidence of
screening for CRC using gFOBTs showed a relative
mortality risk reduction of 25% for those who attended
at least one round of screening, compared with no
screening [16]. This level of relative risk reduction has
been considered significant enough by many first-world
countries to justify the introduction of at least some
limited form of CRC screening [17]. According to
Church, the “best evidence to date does not support a
large difference in effectiveness of the three main
approaches to CRC screening (FOBT, flexible sigmoidos-
copy and colonoscopy)” and so “the US approach of
recommending all three screening strategies seems
sound” [18]. However, basing screening strategies on the
evidence of effectiveness alone downplays the import-
ance of potential harms in determining the benefit-to-
harm trade-off of screening.
Colonoscopy is widely regarded as the reference standard
for CRC screening, but its use as a screening tool has the
potential to cause considerable harms. Although colonos-
copy will find most, but not all, cancers and advanced
adenomas [1], it is an invasive procedure that may lead to
severe bleeding (particularly if biopsy of polyps is per-
formed as part of the procedure), perforation of the bowel
and even death. Fortunately, these severe adverse events
from colonoscopy are rare. A study published in 2008 esti-
mated pooled rates of colonoscopy-related bleeding at
1.64/1,000, perforation at 0.85/1,000, and death at 0.074/
1,000 [19]. Other downsides include the unpleasant bowel
preparation, sedation that can lead to cardiopulmonary
complications, and a colonoscopy miss rate for large
adenomas of 6-12% and 5% for cancers [1]. The potential
downsides of flexible sigmoidoscopy are fewer and less
severe than those for colonoscopy, but are still present [2].
A harm minimization strategy favors a non-invasive
screening test over an invasive one, so making FOBT
preferable to colonoscopy or flexible sigmoidoscopy.
While colonoscopy is necessary as a diagnostic test for
colorectal cancer, it is not essential as a screening test
for people at average risk. The purpose of screening
average risk persons is not to diagnose, but to identify
those at higher risk of having CRC. Rather than using
invasive tests as the screening tool, and potentially sub-
jecting all those being screened to serious harms, it
seems more prudent to focus on detecting the strongest
predictor of CRC – microscopic amounts of blood in
feces – by using the safer and much less expensive
iFOBT to identify those at greater risk of developing
CRC. By doing so, the potential for serious harm from an
invasive test will be limited to those who have the most to
gain from screening, that is, those who have a positive
FOBT and are at higher risk of developing CRC – those
with a positive FOBT are 12-40 times more likely to have
CRC than those with a negative test [20]. Furthermore,
there is a significant body of evidence demonstrating
the superior accuracy of iFOBTs over the older, less
sensitive gFOBTs used in the original CRC screening
trials [21-25]. Because iFOBTs are more accurate, use
of these tests can reduce harms relative to gFOBT by
reducing the number of people who are subjected
unnecessarily to invasive investigations.
Recent data from Australia has shown one iFOBT has
produced a positive predictive value (PPV) for cancer of
4.3%, for advanced adenomas of 23% and for non-
advanced adenomas of 25%, giving an overall PPV for
neoplastic lesions of 52.3% [26]–remarkably high given
the test positivity rate was 7.7%. In other words, 3.3
cancers were found for every 1,000 people screened, and
this figure would be much higher if screening covered
the entire age range of 50-75 years, rather than just 50,
55 and 65 year olds currently offered screening in
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Australia, because the yield of significant pathology is
higher in older people. Such a high level of sensitivity
allows selective detection of advanced adenomas over
non-advanced adenomas, and provides a means of
focusing on the strongest predictor of CRC (fecal blood),
while ignoring the much larger numbers of non-
advanced adenomas that are not a direct threat to an
individual’s health.
Another potential method to minimize harms is to
further target the population for CRC screening by
sex as well as age. For example, a recent study found
the prevalence of advanced adenomas in men aged
45-49 years of age was comparable with women aged
55-59 years [27] raising the possibility of starting
CRC screening later in women.
2) Optimization of economic efficiency.
Restricting colonoscopy to those at the highest risk of
having CRC also makes sense from a resource allocation
point of view, especially given the limitations resource
constraints have been shown to have on full program
implementation [28]. However, a large percentage of col-
onoscopies performed in the US and Australia do not
follow expert guidelines. Goodwin et al. found that
46.2% of a large sample (24,071) of US Medicare patients
who had a negative colonoscopy underwent a repeated
examination in fewer than seven years, rather than the
recommended 10 years, with 23.5% of the whole sample
doing so with no clear clinical indication [29]. In
Australia, over 440,000 colonoscopies were performed
annually in 2005-06, with 75% of these undertaken in
the private sector, and these figures are increasing by
around five percent per year [30]. The significant growth
in colonoscopies nationwide since 1995 suggests that
colonoscopy is being used as a primary screening and
surveillance tool [30], instead of iFOBTs as the Australian
National Health & Medical Research Council (NHMRC)
guidelines recommend. An alternative approach to inva-
sive modes of CRC screening is supported by recent evi-
dence from a systematic review [31] and modeling of CRC
symptoms [32]. These studies identified population
subgroups at higher risk of CRC, with increasing age,
rectal bleeding and weight loss being the most accur-
ate predictors of CRC. The systematic review con-
cluded that, given the current evidence, “it seems
wise to channel resources for cancer detection to-
wards population based screening programs using
FOBT rather than relying on identifying all cancers
and precancerous polyps through investigating people
with symptoms” [31]. Focusing on FOBT as the pri-
mary screening test can avoid unnecessary and wasteful
use of resources that could then be redirected to other
areas of the program. For example, if non-compliance
with the NHMRC guidelines, and the resultant overly
frequent and inappropriate use of colonoscopy, was
addressed, it would free up colonoscopy capacity and en-
able the implementation of a full biennial iFOBT
screening program for those aged over 50, as per the
NHMRC guidelines, instead of the current limited
program. Annual FOBT screening, where offered,
could also be pared back to biennial, resulting in sig-
nificant cost savings, while still delivering a relative
risk reduction of up to 21% compared with a maximum
estimate of 33% for annual screening as found in the
Minnesota trial [33]. Such cost savings could then be put
to worthwhile use within the CRC screening program.
3) Maximization of equity of access.
Savings from redirection of resources currently used
for colonoscopy not recommended in the guidelines
could be used not just to extend services, but to stra-
tegically address inequities in access to screening, by
allowing all those who stand to benefit from screening
to access it if they choose to do so. The opportunity
costs from less efficient allocation of resources may not
only result in adverse economic impacts, but also in un-
desirable ethical ones. Unless screening is available to
all, regardless of a person’s ability to pay, those denied
screening on economic grounds face potentially higher
rates of CRC morbidity and mortality. If resources were
redirected, more funding would become available to
subsidize subsequent colonoscopy follow-up for those
with positive tests, to support national advertising cam-
paigns to increase awareness of CRC screening, to
develop decision aids to help potential screenees assess
the relative benefits and harms of screening based on
their own values and risk, and to implement more tar-
geted approaches to those populations that are less likely
to participate. It is important to note that the objective
of maximizing access to screening is not the same as
maximizing participation. The primary concern should
be offering a screening test that has been shown to be
effective to all those who may benefit from it, while
respecting their right to decline the test [5].
There is substantial evidence of inequitable participation
in CRC screening programs. For example, in Australia, In-
digenous Australians are significantly less likely to partici-
pate in CRC screening than non-Indigenous Australians
[34], while in the UK, von Wagner and colleagues found
reduced uptake of CRC screening in the most ethnically
diverse and lower socioeconomic areas [35]. Levin has
demonstrated the unequal distribution of reduced CRC
mortality rates across the US which is strongly correlated
with the uptake of screening [36]. The use of iFOBT by
Kaiser Permanente in Northern California has contributed
to a substantial increase in the CRC screening rate from
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37% to 75% and in the Medicare population from 41% to
85% between 2005 and 2011 [36] − unprecedented levels
of participation. Importantly, this increased screening rate
is associated with earlier staging of CRC and a reduced
incidence of CRC [36]. Such success has led Levin to
comment that “The question facing clinicians and health
care delivery system policy and decision makers is no
longer whether to use FIT [fecal immunochemical test] as
part of the screening menu of options, but which FIT to
use and how to optimize FIT use” [36].
Summary
Apart from the essential criterion of all cancer screening
programs – reduction in mortality and morbidity – there is
a range of potential additional objectives for screening pro-
grams including: prevention of disease, maximising partici-
pation, facilitating informed decision-making by screenees,
minimising harms, optimising economic efficiency and
maximising equity of access. In cases where there are sev-
eral possible screening modalities, such as colorectal cancer
screening, the preferred objectives will largely determine
the choice of test. We have argued that because CRC
screening with iFOBTs satisfies three important objectives
– minimizing harms, optimizing economic efficiency and
maximizing equity of access – it should be the preferred
colorectal cancer screening strategy for countries with ei-
ther opportunistic or nationally-organized CRC screening
programs. Individuals should be initially offered iFOBT but,
following informed discussion of all the options, may
choose another colorectal cancer screening test, or choose
not to be screened at all.
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